# 1,4 Dihydropyridine derivatives useful in the treatment of cardiovascular disorders, and a process for producing the derivatives.

## Abstract
The present invention relates to novel 1,4 dihydro pyridine derivatives of the following formulae. The compounds have activity as calcium antagonists useful for the treatment of cardiovascular disorders. More particularly, the invention includes preferred compounds which in addition to the usefulness associated with calcium antagonism also exhibit positive inotropic effect without the usual accompanying negative inotropic effect. Thus, the preferred compounds additionally provide beneficial increased myocardial activity.

## Claims
CLAIMS for the Contracting States BE, CH, DE, FR, GB,IT, LI, LU, NL, SE 1. A compound having the following general formula I EMI37.1 and a pharmaceutically acceptable salt thereof wherein R is 1 hydrogen 2 lower alkyl of from one to four carbon atoms, optionally substituted with an amino group having the formula NR7R8 in which R7 and R8 are independently hydrogen or lower alkyl of from one to four carbon atoms, or R7 and Rg, when taken together with the nitrogen atom to which they are attached form a fiveor six membered ring having four or five CH2 groups or 3 an arylalkylene radical in which the aryl part is phenyl optionally substituted with ode or more of i halo, ii trifluoromethyl, iii nitro, iv amino v mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together represent an alkylene of from one to six carbon atoms, vi cyano, vii lower alkoxy of from one to four carbon atoms, viii lower alkyl of from one to four carbon atoms, ix lower thioalkyl of from one to four carbon atoms and in which the alkylene part has from one to four carbon atoms R2 and R3, which may be the same or different, are each hydrogen, lower alkyl of from one to four carbon atoms, cyano, nitro, CO2R4 in which R4 is hydrogen or lower alkyl of from one to four carbon atoms, optionally substituted with amino, mono , or dialkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms R11 R5, and R6, which may be the same or different, are each 1 lower alkyl of from one to four carbon atoms, optionally substituted with a an amino group having the formula NR7R8 in which R7 and Rug are independently hydrogen or lower alkyl, or R7 and Rg, when taken together with the nitrogen atom to which they are attacked form a five or six membered ring having four or five carbon atoms, b ORg in which Rg is hydrogen or lower alkyl of from one to four carbon atoms, or c CO2R4 in which R4 is as defined above 2 cycloalkyl of from four to seven carbon atoms 3 phenyl optionally substituted with On e, or more of i alkyl having from one to four carbon atoms, ii halo, iii trifluoromethyl, iv nitro, v amino, vi mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms vii cyano, viii lower alkoxy of from one to four carbon atoms, and ix lower thioalkyl of from one to four carbon atoms 4 arylalkylene in which the aryl part is phenyl optionally substituted with one or more of i alkyl of from one to four carbon atoms, ii halo, iii trifluoromethyl, iv nitro, v amino, vi mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms vii cyano, viii lower alkoxy of from one to four carbon atoms, and ix lower thioalkyl of from one to four carbon atoms and the alkylene part has from one to four carbon atoms or 5 heteroaryls and wherein R2 and R5 may also be taken together to form a five or six membered ring having, as a member of the ring, aEMI39.1 group n is zero or an integer of one o two m is zero or an integer of from one to six and with the proviso that when n is 0, then R1 cannot be lower alkyl or cycloalkyl. 2. A compound of the formula II EMI39.2 and a pharmaceutically acceptable salt thereof wherein R is 1 hydrogen 2 lower alkyl of from one to four carbon atoms, optionally substituted with an amino group having the formula NR7R8 in which R7 and R8 are independently hydrogen or lower alkyl of from dne to four carbons, or R7 and R8, when taken together with the nitrogen atom to which they are attached form a five or six membered ring having four or five CH2 groups or 3 an arylalkylene radical in which the aryl part is phenyl optionally substituted with one or more of i halo, ii trifluoromethyl, iii nitro, iv amino, iv mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together represent an alkylene of from one to six carbon atoms, vi cyano, vii lower alkoxy of from one to four carbon atoms, viii lower alkyl of from one to four carbon atoms, ix lower thioalkyl of from one to four carbon atoms and the alkylene part has from one four carbon atoms R2 and R3, which may be the sameFor different, are each hydrogen, lower alkyl of from one to four carbon atoms, cyano, nitro, CO2R4 in which R4 is hydrogen or lower alkyl of from one to four carbon atoms, optionally substituted with amino, mono , or dialkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms R1, R5, and R6, which may be the same or different, are each 1 lower alkyl of from one to four carbon atoms, optionally substituted with a an amino group having the formula NR7R8 in which R7 and R8 are independently hydrogen or lower alkyl, or R7 and Rg, when taken together with the nitrogen atom to which they are attacked form a five or six membered ring having four or five carbon atoms, b ORg in which Rg is hydrogen or lower alkyl of from one to four carbon atoms, or c CO2R4 in which R4 is as defined above 2 cycloalkyl of from four to seven carbon atoms 3 phenyl optionally substituted with one or more of li alkyl having from one to four carbon atoms, ii halo, iii trifluoromethyl, iv nitro, v amino, vi mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms vii cyano, viii lower alkoxy of from one to four carbon atoms, and ix lower thioalkyl of from one to four carbon atoms 4 arylalkylene in which the aryl part is phenyl optionally substituted with one or more of i alkyl of from one to four carbon atoms, ii halo, iii trifluoromethyl, iv nitro, v amino, vi mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent at alkylene of from one to six carbon atoms vii cyano, viii lower alkoxy of from one to four carbon atoms, xi lower thioalkyl of from one to four carbon atoms and the alkylene part has from one to four carbon atoms or 5 heteroaryls and wherein R2 and R5 may also be taken together to form a five or six membered ring having, as a member of the ring, aEMI41.1 group n is zero or an integer of one or two and m is zero or an integer of from one to six 3. A compound according to Claim 1 or 2, whereinR2 is cyano and n is one or two. 4. A compound according to Claim 1 or 2, and beina of the formulaEMI42.1 wherein X is CH2 or an oxygen atom. 5. A compound according to Claim 1 or 2, whereinR is hydrogen, R2 is cyano, R3 is C02R4, R5 is methyl and m is one. 6. A compound according to Claim 1 or 2, whereinR is hydrogen, R2 and R3 are independently C02R4, R5 is methyl and m is one. 7. A compound according to Claim 4, 5 or 6, wherein n is zero. 8. A compound according to Claim 1 or 2 having one of the following names ethyl 5 cyano 1,4 dihydro 6 methyl 2 phen ylthio methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate 3 pyridinecarboxylic acid, 5 cyano 1,2,3,4 tetrahydro 2 phenylthio methylene 6 methyl 4 2 trifluoromethyl phenyl , ethy ester 3 quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro 5 oxo 2 phenylthio methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 quinolinecarboxylic acid, 1,2,3,4,5,6,7,8 octahydro 5 oxo 2 phenylthio methylene 4 2 trifluoromethyI phenyll , ethyl ester ethyl 5 cyano 1,4 dihydro 6 methyl 2 2methylphenyl thio methyl 4 2 trifluoromethyl phenyll 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylylthio methyl 4 3 nitrophenyl 3 pyridinecarboxylate ethyl 4 2 chlorophenyl 5 cyano 1,4 dihydro6 methyl 2 phenylthio methyl 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 4pyridinylthio methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylatei 3 pyridinecarboxylic acid, 5 cyano 2 4 1,1 dimethylethyl 2 methylphenyl thio methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylthio methyl 4 82 trifluoromethyl phenyl 5 pyridinecarboxylate 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 2 4 methoxyphenyl thio methyl 6 methyl 4 2 trifluoromethylphenyl , ethyl ester 3 pyridinecarboxylic acid, 2 2 chlorophenylthio methyl 5 cyano 1,4 dihydro 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 2 2fluorophenyl thio methyl 1,4 dihydro 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 2 4 acetylamino phenyl thio methyl 5 cyano 1,4 dihydro6 methyl 4 2 trifluoromethyl phenyl , ethyl ester, 3 pyridinecarboxylic acid, 2 4 chlorophenyl thio methyl 5 cyano 1,4 dihydro 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 4 phenyl 2 phenylthio methyl , ethyl ester Isomer A 3 pyridinecarboxylic acid, 5 cyano 4 2furanyl 1,4 dihydro 6 methyl 2 phenythio methyl, , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 4 2 phenyl 1H imidazol 4yl 2 phenylthio methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 2 phenylthio methyl 4 2 pyridinyl , ethyl ester, 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 2 2 pyridinylthio methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 6 2 8 phenylthio methyl 4 2 trifluoromethyl phenyl , 2 cyanoethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 6 2 8 phenylthio methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylic acid, 5 cyano l,4 dihydro 6 methyl 6 2 8 phenylthio methyl 4 2 trifluoromethyl phenyl , 1 methylethyl ester7 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 6 2 8 phenylthio methyl 4 2 trifluoromethyl phenyl , methyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 6 2 8 phenylthio methyl 4 2 trifluoromethyl phenyl , 2 propenyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro2 methyl 6 phenylthio methyl 4 2 trifluoro methyl phenyl , diethyl ester3 3,5 pyridinecarboxylic acid, 1,4 dihydro6 methyl 2 2 methylphenyl thio methyl 4 2 trifluoromethyl phenyl diethyl ester 3,5 pyridinecarboxylic acid, 1,4 dihydro2 methyl 6 2 pyridinylthio methyl 4 2 trifluoromethyl phenyl , diethyl ester 3,5 pyridinecarboxylic acid, 1,4 dihydro 2 methyl 6 4 pyridinylthio methyl 4 2 trifluoromethyl phenyl , diethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro2 methyl 4 2 phenyl 1H imidazol 4 yl 6 phenylthio methyll , diethyl ester 3,4 bipyridine 3 ,5 dicarboxylic acid, 1 ,4 dihydro 2 methyl 6 phenylthio methyl , diethyl esterj 3,5 pyridinedicarboxylic acid, 2 2 chlorophenyl thio methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyll , 3 ethyl 5 methyl ester ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate3 ethyl 5 cyano 1,4 dihydro 6 methyl 2 2 methylphenyl sulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate, ethyl 5 cyano 1,4 dihydro 6methyl 4 3 nitrophenyl 2 phenylsulfinyl methyl 3pyridinecarboxylate, ethyl 5 cyano 1,4 dihydro 6 methyl 2 4 methoxyphenyl sulfinyl methyl 4 2 trifluoromethy phenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfinyl methyll 4 2 chlorophenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 1 4 pyridinesulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate5 3 ,5 pyridinedicarboxylic acid, 1,4 dihydro2 methyl 6 4 pyridinylsulfinyl methyl 4 2 trifluoromethyl phenyl , diethyl ester is ethyl 2 2 chlorophenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate 5 cyano 2 2 dimethylamino ethyl sulfinyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylic acid, ethyl ester ethyl 4 2 chlorophenyl 5 cyano 1,4 dihydro 6 methyl 2 4 pyridinylsulfinyl methyl 3 pyriainecarboxyiate ethyl 5 cyano 4 2,3 dichlorophenyl 1,4dihydro 6 methyl 2 4 pyridinylsulfinyl methyl3 pyridinecarboxylate 5 cyano 1,4 dihydro 6 methyl 2 2 pyrimi dinylsulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylic acid, ethyl ester 5 cyano 1,4 dihydro 6 methyl 2 1 methyl1H imidazol 2 yl sulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylic acid, ethyl ester ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 phenyl 3 pyridinecarboxylate 3,5 pyridinedicarboxylic acid, 2 11 2 chlo ophenyl sulfinyll methylene 6 methyl 1,2,3,4 tetrahydro 4 t 2 trifluoromethyl phenyl 3 ethyl 5 methyl ester 3 pyridine carboxylic acid, 5 cyano 4 cyclohexyl 1,4dihydro 6 methyl 2 phenylsulfinyl methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 4 2 difluoromethoxy phenyl 1,4 dihydro 6 methyl 2 t phenylsulfinyl methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , methyl ester 53.47 mixture of isomers 3 pyridinecarboxylic acid, 5 cyano I,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , 1 methylethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , 2 hydroxyethyl ester, 3 pyridine carboxylic acid, 5 cyano 1,4 dihydro 6 methyl4 2 phenyl 1H imidazol 4 yl 2 phenylsulfinyl methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 2 pyridinylsulfinyl methyl 4 2 trifluoro methyl phenyl , ethyl ester, j 3 pyridine . carboxylic acid, 5 cyano 2 2 fluorophenyl sulfinyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 pyr idine carboxylic acid, 2 4 acetylamino phenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 2 4 chlorophenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyll , ethyl ester, S 3 pyridinecarboxylic acid, 5 cyano 2 3,4 dichlorophenyl sulfinyl methyl 1,4 dihydro 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl 3 quinoline carboxylic acid, 1,4,5,6 7,8 hexahydro 1 methyl 5 oxo 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro 5 oxo2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , ethyl ester, ethyl 3 cyano1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluormethyl phenyl 5 pyridinecarboxylate 3 pyridine carboxylic acid, 5 cyano 1 2 diethylamino ethyll 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , ethyl ester1 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 2 3methoxy 3 oxoprpyl sulfinyl methyl 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 2 2 ethoxy 2 oxoethyl sulfinyl methyl 1,4 dihydro 6 methyl4 2 sulfluoromethyl phenyl , ethyl ester7 2,4 bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro6 methyl 2 phenylsulfinyl methyl ,ethyl ester, 3,5 pyridine dicarboxylic acid,1,4 dihydro 6 methyl 2 2 methylphenyl sulfinyl methyl 4 2 trifloromethyl phenyl , diethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro 2 methyl 6 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , diethyl ester 3,5 pyridinedicarboxylic acid, 1, 4 dihydro 2 methyl 6 2 pyridinylsulfinyl methyl 4 2 trifloromethyl phenyl , diethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro 2 4 methoxyphenyl sulfinyl methyl 6 methyl 4 2 tri fluoromethyl phenyl , diethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro 2 methyl 6 phenylsulfonyl methyl 4 2 trifloromethyl phenyl , diethyl ester ethyl 5 cyano 1,4dihydro 6 methyl 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4dihydro 6 methyl 2 4 methoxyphenyl sulfonyl methyl 4 2 triflorophenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4dihydro 6 methyl 2 2 methylphenyl sulfonyl methyl 4 2 triflorophenyl 3 pyridinecarboxylate ethyl 2 2 clorophenyl sulfonyl methyl 5 cyano 1,4dihydro 6 methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate 3,5 pyridinecarboxylic acid, 2 E 2 chlorophenyl sulfonyl methyl 1,4 dihydro 6 methyl 4 2 trifloromethyl phenyll 3 ethyl, 5 methyl ester ethyl 5 cyano 1,4dihydro 6 methyl 2 4 pyridinlsulfonyl methyl 4 2 tri fluoromethyl phenyl 3 pyridinecarboxylatej 5 cyano 1,4dihydro 6 methyl 2 2 pyridinylsulfonyl methyl 4 2 trifluoromethylOphenyll 3 pyridinecarboxylic acid, ethyl ester, N oxidej ethyl 5 cyano l,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 phenyl 3 pyridinecarboxylatei 2,4 bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro6 methyl 2 phenylsulfonyl methyl , ethyl ester, l oxide 3,4 bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro6 methyl 2 phenylsulfonyl methyl , ethyl ester ethyl 3 cyano1,4 dihydro 6 methyl 2 phenylsulfoxyl methyl 4 2 trifloromethyl phenyl 5 carboxylate pyridine carboxylic acid, 2 4 aminophenyl sulfonyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl esther 2,4 bipyri dine 3 carboxylic acid, 5 cyano 1 ,4 dihydro6 methyl 2 phenylsulfonyl methyl , ethyl esterj 3 pyridinecarboxylic acid, 5 cyano 4 cyclohexyl 6 methyl1,4 dihydro 2 phenylsulfonyl methyl , ethyl esterj 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 l phenylsulfonyl methyl 4 12 trifluoromethyl phenyl , l methylethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl , 2 propenyl ester 3 pyridinecarboxylic acid, 5 cyano 2 4 1,1 dimethylethyl 2 methylphenyl sulfonyl methyl 1,4 dihydro 6 methyl 4 12 trifluoromethyl phenyl , ethyl ester 3 pyridine carboxylic acid, 5 cyano 2 11 2 fluorophenyl sulfonyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 2 4 chlordophenyl sulfonyl methyl 5 cyano l, 4 dihydro 6 methyl 4 C2 trifluoromethyl phenyl , ethyl ester 3 pyridine carboxylic acid, 5 cyano 1,4 dihydro 6 methyl4 3 nitrophenyl 2 phenylsulfonyl methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl , 2,3 dihydroxypropyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 2 f 3 methoxy 3 oxopropyl sulfonyl methyl 6 methyl4 2 trifloromethyl phenyl , ethyl ester 3 gu inol ine carboxylic acid, 1,4,5,6,7,8 hexahydro l methyl 5 oxo 2 phenylsulfonyl methyl 4 2 trifloro methyl phenyl , ethyl ester 3 quinoline carboxylic acid, 1,4,5,6.,7,8 hexahydro 5 oxo 2 phenylsulfonyl methyl 4 2 trifloromethyl phenyl , ethyl ester, 3 quinoline carboxylic acid,1,4,5,6,7,8 hexahydro 1 methyl 5 oxo 2 phenylthio methyl 4 2 trifloro methyl phenyl , ethyl ester. 9. A pharmaceutical composition comprising an effective amount of a compound as claimed in any preceding claim in admixture with a pharmaceutically acceptable carrier or diluent. 10. For use in a method of treating a mammal suffering from a cardiovascular disorder, a compound as claimed in any one of Claims 1 to 8 or a pharmaceutical composition as claimed in Claim 9 11. A process for preparing a compound of the formula I or II as defined in Claims 1 and 2 respectively, which process comprises contacting the compoundsEMI56.1 wherein R1, R2, R4, R5 and R6 are as defined in Claims 1 or 2 in an organic solvent to form a compound of formula Io or IIo EMI57.1 and, if desired, further reacting the product in one or more of the following steps 1 oxygenating the sulphur atom 2 alkylating the nitrogen atom and 3 reacting the C02R4 group to obtain an R3 group other than CO2R4 and optionally forming a pharmaceutically acceptable salt thereof. CLAIMS for the Contracting State AT 1. A process for preparing a compound having the following general formula I EMI58.1 and a pharmaceutically acceptable salt thereof wherein R is 1 hydrogen 2 lower alkyl of from one to four carbon atoms, optionally substituted with an amino group having the formula NR7R8 in which R7 and R8 are independently hydrogen or lower alkyl of from one to four carbon atoms, or R7 and Rg, when taken together with the nitrogen atom to which they are attached form a fiveor six membered ringhaving four or five CH2 groups or 3 an arylalkylene radical in which the aryl part is phenyl optionally substituted with one or more of i halo, ii trifluoromethyl, iii nitro , iv amino v mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together represent an alkylene of from one to six carbon atoms, vi cyano, vii lower alkoxy of from one to four carbon atoms, viii lower alkyl of from one to four carbon atoms, ix lower thioalkyl of from one to four carbon atoms and in which the alkylene part has from one to four carbon atoms R2 and R3, which may be the same or different, are each hydrogen, lower alkyl of from one to four carbon atoms, cyano, nitro, CO2R4 in which R4 is hydrogen or lower alkyl of from one to four carbon atoms, optionally substituted with amino, mono , or dialkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms R1, Rg, and R6, which may be the same or different, are each 1 lower alkyl of from one to four carbon atoms, optionally substituted with a an amino group having the formula NR7R8 in which R7 and R8 are independently hydrogen or lower alkyl, or R7 and R81 when taken together with the nitrogen atom to which they are attacked form a five or six membered ring having four or five carbon atoms, b ORg in which Rg is hydrogen or lower alkyl of from one to four carbon atoms, or c C02R4 in which R4 is as defined above 2 cycloalkyl of from four to seven carbon atoms 3 phenyl optionally substituted with one or more of i alkyl having from one to four carbon atoms, ii halo, iii trifluoromethyl, iv nitro, v amino, vi mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms vii cyano, viii lower alkoxy of from one to four carbon atoms, and ix lower thioalkyl of from one to four carbon atoms 4 arylalkylene in which the aryl part is phenyl optionally substituted with one or more of i alkyl of from one to four carbon atoms, ii halo, iii trifluoromethyl, iv nitro, v amino, vi mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms vii cyano, viii lower alkoxy of from one to four carbon atoms, and ix lower thioalkyl of from one to four carbon atoms and the alkylene part has from one to four carbon atoms or 5 heteroaryls and wherein R2 and R5 may also be taken together to form a five or six membered ring having, as a member of the ring, aEMI60.1 group n is zero or an integer of one or two m is zero or an integer of from one to six and with the proviso that when n is 0, then R1 cannot be lower alkyl or cycloalkyl which process comprises contacting the compoundsEMI60.2 wherein R1, R2, R4, R5 and R6 are as defined above in an organic solvent to form a compound of formula Io EMI61.1 and, if desired, further reacting the product in one or more of the following steps 1 oxygenating the sulphur atom 2 alkylating the nitrogen atom and 3 reacting the C02R4 group to obtain an R3 group other than C02Rq and optionally forming a pharmaceutically acceptable salt thereof. 2. A process for preparing a compound of the formula II EMI61.2 and a pharmaceutically acceptable salt thereof wherein R is 1 hydrogen 2 lower alkyl of from one to four carbon atoms, optionally substituted with an amino group having the formula NR7R8 in which R7 and R8 are independently hydrogen or lower alkyl of from one to four carbons, orR7 and Rg, when taken together with the nitrogen atom to which they are attached form a five or six membered ring having four or five CH2 groups or 3 an arylalkylene radical in which the aryl part is phenyl optionally substituted with one or more of i halo, ii trifluoromethyl, iii nitro, iv amino, iv mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together represent an alkylene of from one to six carbon atoms, vi cyano, vii lower alkoxy of from one to four carbon atoms, viii lower alkyl of from one to four carbon atoms, ix lower thioalkyl of from one to four carbon atoms and the alkylene part has from one to four carbon atoms R2 and R3, which may be the same or different, are each hydrogen, lower alkyl of from one to four carbon atoms, cyano, nitro, CO2R4 in which R4 is hydrogen or lower alkyl of from one to four carbon atoms, optionally substituted with amino, moao , or dialkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms R1, R5, and R6, which may be the same or different, are each 1 lower alkyl of from one to four carbon atoms, optionally substituted with a an amino group having the formula NR7R8 in which R7 and R8 are independently hydrogen or lower alkyl, or R7 and R8, when taken together with the nitrogen atom to which they are attacked form a five or six membered ring having four or five carbon atoms, b ORg in which Rg is hydrogen or lower alkyl of from one to four carbon atoms, or c C02R4 in which R4 is as defined above 2 cycloalkyl of from four to seven carbon atoms 3 phenyl optionally substituted with one or more of i alkyl having from one to four carbon atoms, ii halo, iii trifluoromethyl, iv nitro, v amino, vi mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamino, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms vii cyano, viii lower alkoxy of from one to four carbon atoms, and ix lower thioalkyl of from one to four carbon atoms 4 arylalkylene in which the aryl part is phenyl optionally substituted with one or more of i alkyl of from one to four carbon atoms, ii halo, iii trifluoromethyl, iv nitro, v amino, vi mono or di alkylamino in which the or each alkyl is independently a lower alkyl of from one to six carbon atoms or, in the case of a dialkylamiAo, in which the two alkyls, when taken together, represent an alkylene of from one to six carbon atoms vii cyano, viii lower alkoxy of from one to four carbon atoms, ix lower thioalkyl of from one to four carbon atoms and the alkylene part has from one to four carboniaztoms or 5 heteroaryls and wherein R2 and R5 may also be taken together to form a five or six membered ring having, as a member of the ring, aEMI63.1 group n is zero or an integer of one or two and m is zero or an integer of from one to six. which process comprises contacting the compounds EMI64.1 wherein R1, R2, R4, R5 and R6 are as defined above in an organic solvent to form a compound of formula fIo EMI64.2 and, if desired, further reacting the product in one or more of the following steps 1 oxygenating the sulphur atom 2 alkylating the nitrogen atom and 3 reacting the CO2R4 group to obtain an R3 group other than dd2R4 and optionally forming a pharmaceutically acceptable salt thereof. 3. A process according to Claim 1 or 2, whereinR2 is cyano and n is one or two. 4. A process according to Claim 1 or 2, for preparing a compound of theEMI65.1 EMI65.2 wherein X is CH2 or an oxygen atom. 5. A process according to Claim 1 or 2, wherein R is hydrogen, R2 is cyano, R3 is CO2 R4, R5 is methyl and m is one. 6. A process according to Claim 1 or 2, wherein R is hydrogen, R2 and R3 are independently CO2 R4, R5 is methyl and m is one. 7. A process according to Claim 4, 5 or 6, wherein n is zero. 8. A process according to Claim 1 or 2 for preparing a compound having one of the following names ethyl 5 cyano 1,4 dihydro 6 methyl 2 phen ylthio methyll 4 2 trifluorometh l phenyl 3 pyridinecarboxylate3 3 pyridinecarboxylic acid, 5 cyano 1,2,3,4 tetrahydro 2 phenylthio methylene 6 methyl 4 2 trifloromethyl phenyl , ethyl ester 3 quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro 5 oxo 2 phenylthhio methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 quinolinecarboxylic acid, 1,2,3,4,5,6,7,8 octahydro 5 oxo 2 phenylthio methylene 4 2 trifloromethyl phenyl , ethyl ester ethyl 5 cyano 1,4 dihydro 6 methyl 2 2methylphenyl thio methyl 4 2 trifloromethyl phenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylthio methyl 4 3 nitrophenyl 3 pyridinecarboxylate ethyl 4 2 chlorophenyl 5 cyano 1,4 dihydro6 methyl 2 phenylthio methyl 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 4 pyridinylthio methyl 4 I2 trifluoromethyl phenyl 3 pyridinecarboxylate 3 pyridinecarboxylic acid, 5 cyano 2 4 1,1 dimethylethyl 2 methylphenyl thiho methyl 1,4 dihydro 6 methyl 4 2 trioifluoromethyl phenyl ethyl ester ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl 5 pyridinecarboxylate 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 2 4 methoxyphenyl thio methyl 6 methyl 4 2 trifluoromethylphenyl , ethyl ester 3 pyridinecarboxylic acid, 2 2 chlorophen ylthio methyl 5 cyano 1,4 dihydro 6 methyl4 2 triflluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 2 2fluorophenyl thio methyl 1,4 dihydro 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 2 4 acetylamino phenyl thio methyl 5 cyano 1,4 dihydro6 methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 2 4 chlorophenyl thio methyl 5 cyano 1,4 dihydro 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano l,4 dihydro 6 methyl 4 phenyl 2 r phenylthio methyl , ethyl ester Isomer A 3 pyridinecarboxylic acid, 5 cyano 4 2furanyl 1,4 dihydro 6 methyl 2 phenylthio methyll , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 4 2 phenyl 1H imidzol 4yl 2 phenylthio methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano l,4 dihydro 6 methyl 2 phenylthio methyl 4 2 pyridinyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 2 pyridinylthio methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 2 phenykthio methyl 4 2 trifluoromethyl phenyl , 2 cyanoethyhl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylic acid, 5rcyano l,4 dihydro 6 methyl 2 phenylthio methyl 4 2 triflluoromethyl phenyl , 1 methylethyl ester. 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl , methyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4dihydro 6 methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl , 2 propenyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro2 methyl 6 phenylthio methyl 4 2 trifluoromethyl phenyl , diethyl ester 3 3,5 pyridinecarboxylic acid, 1,4 dihydro6 methyl 2 2 methylphenyl thio methyl 4 2 trifluoromethyl phenyl diethyl ester 3,5 pyridinecarboxylic acid, 1,4 dihydro2 methyl 6 2 pyridinylthio methyl 4 2 trifluoromethyl phenyl , diethyl ester 3 ,5 pyridinecarboxylic acid, 1,4 dihydro2 methyl 6 4 pyridinylthio methyl 4 2 trifluoromethyl phenyl , diethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro2 methyl 4 2 phenyl 1H imidazol 4 yl 6 phenylthio methyll , diethyl ester 3,4 bipyridine 3 ,5 dicarboxylic acid, lE,4 dihdro 2 methyl 6 l phenylthio methyl , diethyl esterj 3,5 pyridinedicarboxylic acid, 2 t 2 chloro phenyl thio methyl 1,4 dihydro 6 methyl 4 t2 trifluoromethyl phenyll r 3 ethyl 5 methyl ester ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 12 trifluoromethyl phenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 2 methylphenyl sulfinyl methyl 4 2 trifluoro methyl phenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 4 3nitrophenyl 2 phenylsulfinyl methyl 3pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 1 4 methoxvphenyl sulfinyll methyl 4 I2 trifluoro methyl phenyll 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro methyl 2 phen ylsulfinyl methyl 4 2 chlorophenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4 dihydro 6 methyl 2 4pyridinylsulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate 3,5 pyridinedicarboxylic acid, 1,4 dihydro2 methyl 6 4 pyridinylsulfinyl methyl 4 2 trifluoromethyl phenyl , diethyl ester is ethyl 2 2 chlorophenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyll 3 pyridinecarboxylatej S cyana a 2 dimethylamino ethlrll sul finyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl9 3 pyridinecaarboxylic acid, ethyl ester t ethyl 4 2 chlorophepnyl 5 cyano 1,4 dihydro6 methyl 2 4 pyridinylsulfinyl methyl 3pyridinecarboxylate ethyl 5 cyano 4 2,3 dichlorophenyl 1,4dihydro 6 methyl 2 4 pyridinylsulfinyl methyl 3 pyridinecarboxylatej 5 cyano 1,4 dihydro 6 methyl 2 2 pyrimi dinylsulfinyl methyl 4 2 triflluoromethyl phenyl 3 pyridinecarboxylic acid, ethyl ester 5 cyano 1,4 dihydro 6 methyl 2 1 methyl1H imidazol 2 yl aulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylic acid, ethyl ester ethyl 5 cyano 1,4 dihydro 6 methyl 2 phen ylsulfinyl methyl 4 phenyl 3 pyridinecarbo xylateX 3 ,5 pyridinedicarboxylic acid, 2 I1 a chlorophenyl sulfinyll methylene 6 methyl 1,2,3,4 tetrahydro 4 2trifluoromethyl phpenyl 3 ethyl 5 methyl ester 3 pyridinecarboxylic acid, 5 cyano 4 cyclohexyl 1,4dihydro 6 methyl 2 phenylsulfinyl methyl , ethyl ester 3 pyridinecarboxyllllic acid, 5 cyano 4 2 difluoromethoxy phenyl 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl , methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl2 phenylsulfinyl methyl 4 2 trifluoro methyl phenyli , methyl ester 53.47 mixture of isomers 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl2 phenylsulfinyl methyl 4 2 trifluoromthyl phenyl , 1 methylethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , 2 hydroxyethyl esterj . 3 pyridine carboxylic acid, 5 cyano 1,4 dihydro 6 methyl4 2 phenyl 1H imidazol 4 yl 2 phenylsulfinyl methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl2 2 pyridinylsulfinyl methyl 4 2 trifluoromethyl phenyl , ethyl ester, 3 pyridine carboxylic acid, 5 cyano 2 2 fluorophenyl sulfinyl methyl 1,4,dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 2 4 acetylamino phenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 2 4 chlorophenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyli , ethyl ester, 3 pyridinecarboxylic acid, 5 cyano 2 3,4 dichlorophenyl sulfinyl methyl 1,4 dihydro 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , 3 quinolinecarboxylic acid, 1,4,5,6,7 ,8 bexahydro l methyl 5 oxo 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , ethyl ester 7 3 quinoline carboxylic acid, 1,4,5,6,7,8 hexahydro 5 oxo 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , ethyl ester, t ethyl 3 cyano1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl 5 pyridinecarboxylate 3 pyridine carboxylic acid, 5 cyano 1 E2 diethylamino ethyl 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 f2 trifluoramethyl phenyll , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 2 3methoxy 3 oxopropyl sulfinyl methyl 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 2 2 ethoxy 2 oxoethyl sulfinyl methyl 1,4 dihydro 6 methyl4 12 sulfluoromethyl phenyll , ethyl ester 12,4 bipyri dine 3 carboxylic acid, 5 cyano 1 ,4 dihydro6 methyl 2 phenylsulfinyl methyl , ethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro 6 methyl 2 2 methylphenyl sulfinyl methyl 4 2 trifluoromethyl phenyll, diethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro 2 methyl 6 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , diethyl ester 3 ,5 pyridinedicarboxylic acid, 1, 4 dihydro 2 methyl 6 2 pyridinylsulfinyl methyl 4 2 trifloro methyi phenyl , diethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro 2 4 methoxyphenyl sulfinyl methyl 6 methyl 4 2 tri fluoromethyl phenyl , diethyl ester 3,5 pyridinedicarboxylic acid, 1,4 dihydro 2 methyl 6 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl , diethyl ester ethyl 5 cyano 1,4dihydro 6 methyl 2 phenylsulfonyl methyl 4 2 trifloromethyl phenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4dihydro 6 methyl 2 4 methoxyphenyl sulfonyl methyl 4 2 trifluorophpenyl 3 pyridinecarboxylate ethyl 5 cyano 1,4dihydro 6 methyl 2 2 methylphenyl sulfonyl methyl 4 2 trifluorophenyl 3 pyridinecarboxylate ethyl 2 I 2 chlorophenyl sulfonyl methyl 5 cyano 1,4dihydro 6 methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate 3,5 pyridinecarboxylic acid, 2 2 chlorophenyl sulfonyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl 3 ethyl, 5 methyl ester ethyl 5 cyano 1,4dihydro 6 methyl 2 4 pyridinylsulfonyl methyl 4 12 trifluoromethyl phenyl 3 pyridinecarboxylate 5 cyano 1,4dihydro 6 methyl 2 2 pyridinylsulfonyl methyl 4 12 trifluoromethyl phenyli 3 pyridinecarboxylic acid, ethyl ester, N oxidej ethyl 5 cyano1,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 phenyl 3 pyridinecarboxylate I2,4 bipyri dine 3 carboxylic acid, 5 cyano 1 ,4 dihydro6 methyl 2 phenylsulfonyl methyl , ethyl ester, l oxide 3,4 bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro6 methyl 2 phenylsulfonyl methyl , ethyl ester ethyl 3 cyano1,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl 5 carboxylate num pyridine carboxylic acid, 2 4 aminophenyl sulfonyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester 2,4 bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro 6 methyl 2 C phenyIsulfonyl methyl , ethyl esterj 3 pyridinecarboxylic acid, 5 cyano 4 cyclohexyl 6 methyl 1,4 dihydro 2 phenylsulfonyl methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 1 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl , 1 methylehyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 t phenylsulfonyl methyll 4 12 trifluoromethyl phenyl , 2 propenyl ester 3 pyridinecarboxylic acid, 5 cyano 2 4 1,1 dimethylethyl 2 methylphenyl sulfonyl methyl 1,4 dihydro 6 methyl 4 t2 trifluoromethyl phenyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 2 2 flluorophenyl sulfonyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester 3 pyridine 1 carboxylic acid, 2 4 chlorophenyl sulfonyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester. 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl4 3 nitrophenyl 2 phenylsulfonyl methyl , ethyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl , 2,3 dihydroxypropyl ester 3 pyridinecarboxylic acid, 5 cyano 1,4 dihydro 2 I1 3 methoxy 3 oxopropyl sulfonyl methyl 6 methyl4 2 trifluoromethyl phenyl , ethyl ester 3 guinoline casrboxylic acid, 1,4,5,6,7,8 hexahydro 1 methyl 5 oxo 2 phenylsulfonyl methyl 4 2 trifluoro methyl phenyl , ethyl ester 3 guinoline carboxylic acid, 1,4,5,6 ,7,8 hexahydro 5 oxo 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyll , ethyl ester, 3 quinoline carboxylic acid, 1,4,5,6,7 ,8 hexahydro l methyl 5 oxo 2 phenylthio methyl 4 2 triiofluoro methyl phenyl , ethyl ester. 9. A process for preparing a pharmaceutical composition which process comprises cdmbining an effective amount of a compound prepared by a process as claimed in any preceding claim together with a pharmaceutically acceptable carrier or diluent. 10. For use in a method of treating a mammal suffering from a cardiovascular disorder, a compound prepared by a process as claimed in any one of Claims 1 to 8 or a pharmaceutical composition prepared by a process as claimed in Claim 9.

## Description
1,4 DIHYDROPYRIDINE DERIVATIVES USEFUL IN THE TREATMENTOF CARDIOVASCULAR DISORDERS, AND A PROCESS FOR PRODUCINGTHE DERIVATIVES. More specifically, 1,4 dihydropyridine derivatives substituted in the two position are said to be distin guished by a powerful vessel influencing action in US Patent Number 4,188,395 by Bossert, et al.No mention is made of inotropic effect. British Patent Number 2,112,782 discloses various dihydropyridines not teaching the compounds of the present invention but having increased myocardial contractility. None of the above references teaches the combina tion of substituents on a dihydropyridine moiety of the present invention. More particularly, the 1,4 dihydropyridine derivatives of the present inven tion having Formula I or II are distinguished fromBossert, et al, by the differences in the sulfur containing substituent on the dihydropyridine moiety and, therefore, are not taught by Bossert, et al. Dihydropyridine polyesters have been described in the literature as antihypertensive and antianginal agents. For example, British Patent Number 1,389,509 describes 1,4 dihydropyridine polyesters as coronary agents. Further, disclosure for cardiovascular activity used as antihypertensives, vasodilators, antifibrillatory agents, and also having marked smooth muscle effect is made for 1,2,3,4 tetrahydropyridine 3,5 dicarboxylic acid derivatives in WestGerman Application Number 3,239,273A. Other dihydropyridines are shown to be calcium agonists or cardiotonics in Belgian Patent 893,984. Additional disclosure for various dihydropyridine polyesters having usefulness as cardiovascular agents is found inWest German Application 2,248,150 and Belgian Patents 804,160, 803,474, 861,964, 843,576, and 817,540. Thus, the present novel dihydropyridine derivatives of Formula I or Formula II each as defined hereinafter having valuable calcium antagonist and cardiotonic properties useful for the treatment of cardiovascular disorders are not within the teachings of the prior art. Accordingly, the present invention provides a compound of Formula I and a pharmaceutically acceptable salt thereof wherein R is 1 hydrogen 2 lower alkyl of from one to four carbons, inclusive which is optionally substituted with an amino group such as NR7R8 where tri and R8 are independently hydrogen or lower alkyl, or taken together form a five or six membered ring and 3 aralkyl wherein a ar is phenyl optionally substituted with one or more of halo, nitro, amino, mono or di alkylamino wherein the alkyls when taken together are of from one to six carbons, inclusive, cyano, lower alkoxy of from one to four carbons, inclusive, lower alkyl of from one to four carbons, inclusive, lower thioalkyl of from one to four carbons, inclusive, and b alkyl is alkylene of from one to four carbons, inclusive. R2 and R3 are the same or different and are hydrogen, lower alkyl of from one to four carbons, inclusive, cyano, nitro, R wherein R4 is hydrogenCO24 or lower alkyl of from one to four carbons, inclusive, optionally substituted with amino, mono or dialkylamino wherein the alkyls when taken together are of from one to six carbons, inclusive. R1, R5, and R6 are the same or different and are 1 lower alkyl of from one to four carbons, inclusive, which is optionally substituted with a an amino group, such as N bN where b and R8 are independently hydrogen and lower alkyl which may also be taken together to form a five or sixmembered ring or b ON where R9 is H or lower alkyl of from one to four carbons, inclusive, or c CO2R4, where R4 has same definition as stated above 2 cycloalkyl of from four to seven carbons 3 phenyl optionally substituted with one or more of alkyl of from one to four carbons, inclusive, halo, nitro, amino, mono or di alkylamino wherein the alkyls when taken together are of from one to six carbons, inclusive, cyano, lower alkoxy of from one to four carbons, inclusive, lower thioalkyl of from one to four carbons, inclusive 4 alkyl wherein ar is phenyl optionally substituted with one or more of alkyl of from one to four carbons, inclusive, halo, nitro, amino, mono or di alkylamino wherein the alkyls when together have of from one to six carbons, inclusive, cyano, lower alkoxy of from one to four carbons, inclusive, lower thioalkyl of from one to four carbons, inclusive or 5 heteroaryls. Additionally, h and R5 may also be taken together to form a five or six membered ring having as a member of the ring a C O or C O O group. n is a number of from zero to two, inclusive m is a number of from one to six, inclusive and with the proviso that when n is 0 then R1 cannot be lower alkyl or cycloalkyl. Additionally, the present invention is a compound of the Formula II and a pharmaceutically acceptable salt thereof where possible, e.g., when a basic nitrogen is present, wherein n, R, R1, R2 R3, R5, and R6 are as defined above but where n is 0, then R1 can also be lower alkyl of from one to four carbons, inclusive, and cycloalkyl. The present invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or II as each is defined above with a pharmaceutically acceptable carrier. A therapeutically effective amount comprises a therapeutic cardiovascular effective amount. The compounds of this invention are useful in a method of treating cardiovascular disorders in a mammal, including man, suffering therefrom,which method rrnpri6es administering to such mammals a therapeutically effective amsunt of a compound of Formula I or a compound of Formula II. The preferred compounds of the present invention are 1 the compounds of Formula I and II whereinR2 is CN and n is one or two 2 the compounds of Formula I and II wherein R2 and R5 may also be taken together to form a five or six membered ring having as a member of the ring a C O or sC O O group and n is one or two. The preferred compounds provide increased myocardial contractility giving the compounds greater value as cardiotonic agents for treatment of cardiovascular disorders. These compounds demonstrate only positive inotropic activity in in vitro tests which activity is associated with increased myocardial contractility PCSI . That is, these compounds do not demonstrate undesirable negative inotropic activity usually associated with these types of compounds. The most preferred compounds of the present invention are the compounds of Formula I whereinR2 is CN, R5 is lower alkyl, R3 is CO2R4, m is one, n is one or two, R4 is same as defined above and R1 is phenyl or heteroaryl as defined herein. Also included in the invention are methods using novel compounds of the present invention wherein n is zero having the disclosed utility recited herein as intermediates for the preparation of the 1,4dihydropyridine derivatives of the invention therefrom having sulfinyl or sulfonyl moieties. The salts of the compounds of Formula I orFormula II possible when a basic nitrogen is present, are prepared in a manner which is in itself known by reacting the compounds obtained according to the processes of the invention with suitable acids.For example, the appropriate compounds of FormulaI or II are dissolved in ethanol, then suitable acids are added to the solution. Examples of inorganic and organic acids which form physiologically acceptable acid addition salts with the dihydropyridines of the present invention are hydrogen halide acids, such as hydrochlqric acid and hydrobromic acid, particularly hydrochloric, phosphoric, sulfuric, nitric, monofunctional and bifunctional carboxylic acids and hydroxycarboxylic acids, such as acetic, maleic, succinic, fumaric, tartaric, citric, salicylic, lactic, and l,5 naphthalenedicarboxylic and naphthalenedicarboxylic and naphthalenedisulphonic acids. Lower alkyl or alkyl of from one to four carbons, inclusive, is meant to include a straight or branched chain alkyl group such as methyl, ethyl, propyl, butyl, and isomers thereof. Halogen or halo means fluorine, chlorine, bromine, or trifluoromethyl. Lower alkoxy and lower thioalkyl of from one to four carbons, inclusive is also meant to include methyl, ethyl, propyl, butyl, and isomers thereof. Mono or di alkylamino is meant to include methylamino, dimetbylamino, ethylamino, N methylN ethylamino, propylamino, diisopropylamino, butylamino, N ethyl N ethylamino, N butyl N ethylamino and the like. A heteroaryl means thienyl, furanyl, pyryl, pyridinyl, quinolyl, isoquinolyl, pyrimidyl, pyridazinyl, quinazolyl, quinoxalyl, benzothienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, pyrazinyl, oxazinyl, thiazinyl, indolizinyl, indolyl, benzofuranyl, indazolyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzioxazolyl, benzthiazolyl, benztriazolyl, benzoxadiazolyl, cinnolinyl, phthalaxinyl, naphthyridinyl, or benzothiazinyl. Alkylene of from one to four carbons, inclusive, are methylene, ethylene, propylene, butylene, or isomers thereof. The compounds of Formula I are useful as salts derived from physiologically acceptable acidsThe acids may be mineral acids such as hydrochloric acid, sulfuric acid, and the like, or organic acids, such as ethanesulfonic acid, benzenesulfonic acid, p toluenesulfonic acid, and the like giving the hydrochloride, sulfamate, ethanesulfonate, benzenesulfonate, p toluenesulfonate, and the like, respectively. The compound of Formula I and II of the present invention wherein at least R2 and R3 are not just the same as each other, includes stereoisomers due to the presence of at least one asymmetric carbon atom at the four position of the 1,4 dihydropyridine nucleus and can exist as each optical isomer or a racemic mixture. Further, some of the compounds of Formula I and II which have not less than two asymmetric carbon atoms in its molecule may exist as each diastereomer s or the mixture thereof.The mixture of the diastereomers can be resolved to each racemic compound by conventional resolution methods such as chromatography or fractional recrystallization and the like and the racemic compound can be resolved into each optical isomer by a conventional method for racemic resoaution by fractional recrystallization of a salt of the racemic compound with an optically active acid, e.g., tartaric acid or camphor sulfonic acid. The terms wstereoisomersw and a stereoisomerismw as used throughout this specification and the appended claims are to be given the meaning usually ascribed to them by practitioners of the organic chemical arts, and specifically as defined by Eliel ip. Stereo chemistry of Carbon Compounds, pp 1 6, McGraw Hill, New York, 1962. Generally, the compounds of Formula I and FormulaII wherein n is one or two may be conveniently synthesized by oxidation of the compounds of Formula I and Formula II wherein n is 0, respectively. Such oxidation is accomplished in a manner analogous to those known in the art. See, for example, wOxida tion of Sulfides to Sulfoxides and Sulfonesw inAdvanced Organic Chemistry, Ed. Jerry, March, p.1089, 3rd Edition, John Wiley Sons 1985 . SeeScheme I. The compounds of Formula I and II wherein n is zero are generally prepared by the following procedures. A compound having the Formula III wherein R2 and Rg are as defined above, a compound of the Formula IV wherein R6 is as defined above and a compound of Formula V wherein R1 and R3 are as defined above is contacted in the presence of an inert organic solvent such as ethanol, 1 butanol, or dioxane under reflux condition. The products of the reaction are a mixture of the compounds of Formula 10 and IIo. Such products are recovered and or separated by conventional means such as extraction, distillation, chromatography, and the like. See Scheme II. The compounds of Formula 10 and 11o may optionally be reacted with a compound of Formula RX whereinR is as defined above and X is halogen by conventional methods to further obtain the compounds having a definition of R other than hydrogen. See SchemeIII The desired compound of Formula I or FormulaII is isolated and purified by conventional methods. Such isolation and purification do not neceqsatate any methods not within the skill of the ordinary artisan. Representative novel compounds of Formula I and of Formula II are found to possess inotropic and vasodilatory activity in vitro and as such, these are useful for the treatment of congestive heart failure, coronary heart disease, myocardial ischemia, angina, and hypertension. These are, thus, the cardiovascular disorders noted above to be within the meaning of the present invention. Representative compounds of Formula I and II inhibit niterendipine a reference calcium antagonist binding with an IC50 of 1 x 10 6N to 1 x 10 9M range.These data predict calcium modulator activity beneficial for the utility of the present invention. It is now additionally found that some of the above named preferred compounds advantageously demonstrate positive inotropic effect in vitro. For the preferred compounds of the present invention as defined above, the compounds also produce effects that include increases in contractility and decreases in vascular resistance, with only moderate increases in heart rate in anesthetized dogs. These effects are further complemented by a direct stimulatory effect on the myocardium ire., a positive inotropic effect . The complementary effects are observed in isolated atrial tissue and the effects are not subject to negative inotropic effect. Thus, compounds having the combined activity may provide support to a failing heart without offsetting negative effects usually associated with previously known calcium blocking agents. Additionally, the compounds of the present invention generally exhibit an advantageous vasodilatory effect resulting in the after load reduction associated with calcium antagonists. Test for In Vitro Myocardial Inotropic Activity in Isolated Guinea Pig Atria Adult male guinea pigs weighing 300 400 g are reserpinized 12000 units i.p. and, after ten minutes, are killed by cervical dislocation. The hearts are quickly removed and placed in a physiological salt solution PSS containing 118 mM NaCl, 4.8 mM KC1, 2.4 mM CaCl, 1.2 mM Mug604, 1.0 mM NaH2PO4, 11.1 in dextrose, and 27.2 mM NaHCO3, maintained at pH 7.4 and 3O0C. After removing all superficial blood, the hearts are perfused via the aorta to remove any blood from the coronary arteries.After five to ten minutes of perfusion, the left atria are dissected and mounted vertically in a 50 ml, water jacketed bather containing PSS at 300C and continuously oxygenated with 95 02 5 CO2. The left atria are electrically stimulated at 1.5 Hz.The tissues are equilibrated for 30 minutes and washed with fresh PSS. The stimulation voltage is adjusted to 20 above the threshold and tension adjusted to Lmax the muscle length at which tension development is maximal . The tissues are then equilibrated for an additional 30 minutes, after which the compounds to be examined are added to the tissue bather. The compounds are initially dissolved inDMSO and dilutions made with normal saline, such that the final concentration of DMSO does not exceed 0.5 . The compounds are added in full or half log concentration increments, usually over a concentration range of 1 x 1018 to 1 x 10 4M. The muscles are generally allowed to assume a new steady state contractile response before each subsequent additiqn.of drug. Using this procedure the inotropic activity of preferred compounds of the present invention is shown as found in the following Table 1. The reference calcium antagonist has also been tested for comparison. TABLE 1 Change in Mvocardial Contractilitv PSCI Example commat e io 5M 2 33 2 53 10 30 13 26 16 26 18 33 19 33 The present invention includes a method for treating mammals, including humans, suffering from the diseases noted above by administering to such mammals a corresponding pharmaceutical composition containing a compound of the Formula I as defiled above in appropriate unit dosage form. A physician or veterinarian of ordinary skill readily determines a subject exhibiting symptoms of the diseases.The routes of administration and the dosage forms therefor are from among those conventional to the pharmaceutical art. Regardless of the route of administration selected the invention provides a compound of Formula I, in unit dosage form comprising the compound either alone or in admixture with a pharmaceutically acceptable carrier appropriately selected from those known. An effective but nontoxic quantity of the compoundI is employed in treatment. The dosage regimen is selected in accordance with a variety of factors including the type, age, weight, sex, and medical condition of the mammal, the severity of symptoms of the disease being treated, the route of administration and particular compound of Formula I employed.An ordinarily skilled physician or veterinarian will readily determine and prescribe the effective amount of the compound I to prevent or arrest the progress of the disease condition. In so proceeding, the physician or veterinarian could employ relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained. For convenience, the total daily dosage may be divided and administered in portions during the day if desired. It is understood that the compositions and methods of treatment of the present invention as described above also include the pharmacologically acceptable acid addition salts of the compounds of Formula I and Formula IIx The following Examples further merely illustrate the invention and, therefore, are not meant to be limiting.EXAMPLE 1A Ethyl S coano 1.4 dihodro 6 methYl 2 phenslthiol methyl 4 2 trifluoromethylphenyl 3 pyridinecarboxylate A solution of 2 trifluoromethyl benzaldehyde 3.48 g, 0.02 mole , 3 aminocrotononitrile 1.6 g, 0.02 mole and ethyl 3 oxo 4 phenylthio butanoate 4.76 g, 0.02 mole in ethanol 50 ml is refluxed for 24 hours. The solution is concentrated to a brown oil from which the above product is isolated by chromatography on silica gel with isopropyl ether as eluent. The crude product was crystallized from ethyl acetate to give analytically pure material mp 122 1230C. Anal. calcd. for C24H21F3O2N2S C, 62.88 H, 4.58 N, 6.11Found C, 62.85 H, 4.73 N, 6.01EXAMPLE 1B The chromatographic separation also provides the isomeric compound 3 pyridinecarboxylic acid, 5 cyano 1,2,3,4 tetrahydro 2 phenylthio methylene 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 146 1480C.Anal. calcd. for C24H21F3O2N2S C, 62.87 H, 4.61 N, 6.1 S, 6.99Found C, 63.40 H, 4.83 N, 6.31 S, 6.91 Similarly, by substituting amino cyclohexen3 one for the 3 aminocrotononitrile in Example 1A one obtains EXAMPLE 1C 3 Quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro 5 oxo 2 l phenylthio methyl 4 t2 trifluoromethyl phenyl , ethyl ester mp 176 1770C. Chromatographic separation also provides the isomeric compound as follows EXAMPLE 1D 3 Quinolinecarboxylic acid, 1,2,3,4,5,6,7,8 octahydro 5 oxo 2 phenylthio methylenel 4 12 trifluoromethyl phenyl , ethyl ester mp 204 2050C. EXAMPLE 1EEthyl s cyano 1,4 dihydro 6 methyl 2 1 2 methylphenyl thioamethyl 4 2 trifluoromethyl phenyll 3 pyridine carboxylate mp 146 1480C. EXAMPLE 1FEthyl 5 cyano 1,4 dihydro 6 methyl 2 l phenylthio methyl 4 3 nitrophenyl 3 pyridinecarboxylate mp 122 123 0C. EXAMPLE 1GEthyl 4 2 chlorophenyl 5 cyanol 1,4 dihydro 6 methyl2 phenylthio methyl 3 pyridinecarboxylate mp 161 162 C.EXAMPLE 1HEthyl 5 cyano 1,4 dihydro 6 methyl 2 4 pyridinylthio methyl 4 12 trifluoromethyl phenyl 3 pyridinecarboxylate mp 229 230 0C Also, similarly, by using appropriate corresponding starting materials in the procedure described in Example ZA, the following compounds are obtained. EXAMPLE 1I 3 Pyridinecarboxylic acid, 5 cyano 2 ethyl 2 methylphenyl thioamethyll 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 126 128 C.EXAMPLE 1JEthyl 3 cyano 1,4 dihydro 6 methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl 5 pyridinecarboxylate mp 144 145 C.EXAMPLE 1K 3, Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 2 t 4 methoxyphenyl thio methyl 6 methyl 4 2 tri fluromethylphenyl , ethy ester mp 108 109 C EXAMPLE 1L 3 Pyridinecarboxylic acid, 2 2 chlorophenylthio methyl3 5 cyano 1,4 dihydro 6 methyl 4 12 trifluoro methyl phenyl , ethyl ester mp 172 1730C.EXAMPLE 1M 3 Pyridinecarboxylic acid, 5 cyano 2 2 fluoro phenyl thioZmethylJ 1,4 dihydro 6 methyl 4 2 tri fluoromethyl phenyl , ethyl ester mp 121 122 C. EXAMPLE 1N 3 Pyridinecarboxylic acid, 2 4 acetyl amino phenyl thio methyl 5 cyano 1,4 dihydro 6methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 187 189 C.EXAMPLE 10 3 Pyridinecarboxylic acid, 2 84 chlorophenyl thio methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl9 , ethyl ester mp 107 109 C.EXAMPLE 1P 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 4 phenyl 2 phenylthio methyl , ethyl ester Isomer A mp 168 170 0C. EXAMPLE 1Q 3 Pyridinecarboxylic acid, 5 cyano 4 2 furanyl 1,4 dihydro 6 methyl 2 phenylthio methyl , ethyl ester mp 109 110 C.EXAMPLE 1R 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 4 2 phenyl lH imidazol 4 yl 2 l phenylthio methyl, ethyl ester mp 198 199 0C. EXAMPLE 1S 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylthio methyl 4 2 pyridinyl , ethyl ester mp 164 167 C. EXAMPLE 1T 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 2 pyridinylthio methyl 4 2 trifluoro mthyl phenyl , ethyl ester mp 179 180 0C. EXAMPLE 1U 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl , 2 cyanoethyl ester mp 158 160 C.EXAMPLE 1V 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 phenylthio methyl 4 t2 trifluoromethyl phenyl mp 204 2060C. EXAMPLE 1W 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 t phenylthio methyl 4 12 trifluoromethyl phenyl , l methylethyl ester mp l23 1250C. EXAMPLE 1X 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl , methyl ester mp 117 118 C.EXAMPLE 1Y 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl , 2 propenyl ester mp 113 114 0C. EXAMPLE 1Z Following the procedure of Example 1A and by substituting ethyl 3 aminocrotonate in place of 3 aminocrotononitrile, one obtains 3,5 pyridinedicarboxylic acid, 1,4 dihydro 2 methyl 6 phenylthio methyl 4 2 trifluoromethyl phenyl , diethyl ester mp 129 130 0C. Anal. calcd. for C26H26F304NS C, 61.72 H, 5.14 N, 2.76 S, 6.33Found C, 61.98 H, 5.31 N, 2.74 S, 6.37EXAMPLE IAA 3,5 Pyridinecarboxylic acid, 1,4 dihydro 6 methyl2 2 methylphenyl thio methyl 4 2 trifluoromethyl phenyl , diethyl ester mp 117 119 C. Similarly by using appropriate starting materials in the procedure described in Example 1Z, the following additional analogs are obtained.EXAMPLE 1BB 3, 5 Pyridinedicarboxylic acid, l,4 dihydro 2 methyl 6 2 pyridinylthio methyll 4 t2 trifluoromethyl phenyl , diethyl ester mp 118 119 C.EXAMPLE lCC 3,5 Pyridinedicarboxylic acid, 1,4 dihydro 2 methyl 6 4 pyridinylthio methyl 4 2 trifluoromethyl phenyll , diethyl ester mp 146 148 0C. EXAMPLE 1DD 3 ,5 Pyridinedicarboxylic acid, 1,4 dihydro 2 methyl4 2 phenyl 1H imidazol 4 yl 6 phenylthio methyl , diethyl ester mp 179 1800C. EXAMPLE 1EE 3,4 Bipyridine 3 ,5 dicarboxylic acid, 1 ,4 dihydro 2 methyl 6 phenylthio methyl , diethyl ester mp 116 118 0C. EXAMPLE 1FF 3,5 Pyridinedicarboxylic acid, 2 2 chlorophenyl thio methyl 1,4 dihydro 6 methyl 4 12 trifluoro methyl phenyl , 3 ethyl 5 methyl ester mp 123 125 0C. EXAMPLE 2Ethyl 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridine carboxvlate m Chloroperbenzoic acid 0.43 g, 0.002 mole is added to a solution of ethyl 5 cyano 1,4 dihydro6 methyl 2 phenylthio methyl 4 2 trifluoromethylphenyl 3 pyridinecarboxylate as prepared above in Example 1 0.96 g, 0.002 mole in 20 ml of dichloro methane with stirring at 0 0C. The solution is stirred for two hours at 0 0C to complete the reaction. The solution is washed with 10 aqueous potassium carbonate solution followed by water, dried, and stripped to give a semisolid product. This is purified by chromatography to give two isomers of ethyl 5 cyano 1,4 dihydro 6methyl 2 phenylthio methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate.Isomer A, mp 120 122 CAnal. calcd. for C24H21F3N203S C, 60.75 H, 4,40t N, 5.90Found C, 60.35 H, 4.38 N, 5.89 Isomer B, mp 183 185 0C Anal. calcd. for C24H21F3N203S C, 60.75 H, 4.40 N, 5.90Found C, 60.72 H, 4.59 N, 5.83 By following the procedure described in theExample 2 and using substrates selected from amongExamples 1 the following additional sulfinyl derivatives are obtained.EXAMPLE 2AEthyl 5 cyano 1,4 dihydro 6 methyl 2 2 methylphenyl sulfinyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate mp 176 180 C.EXAMPLE 2BEthyl 5 cyano l, 4 dihydro 6 methyl 4 3 nitrophenyl 2 phenylsulfinyl methyl 3 pyridinecarboxylate mp 194 195 C Isomer A mp 168 1700C isomer fl . EXAMPLE 2CEthyl 5 cyano 1,4 dihydro 6 methyl 2 4 methoxy phenyl sulfinyllmethyl 4 t2 trifluoromethyl phenyl 3 pyridinecarboxylate mp 151 154 0C diastereoisomers .EXAMPLE 2DEthyl 4 2 chlorophenyl 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfiny1 methyl 3 pyridinecarboxylatei mp 198 202 0C diastereoisomers .EXAMPLE 2EEthyl 5 cyano 1,4 dihydro 6 methyl 2 4 pyridinylsulfinyl methyl 4 2 trifluoromethyl phenyl 3pyridinecarboxylate mp 202 2030C dec Isomer A . EXAMPLE 2F 3 ,5 Pyridinedicarboxylic acid, 1,4 dihydro 2 methyl6 4 pyridinylsulfinyl methyl 4 2 trifluoromethyl phenyl , diethyl ester mp 202 203 C.EXAMPLE 2GEthyl 2 2 chlorophenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate mp 174 1840C.EXAMPLE 2H 5 Cyano 2 ttt2 dimethylamino ethyl sulfinyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylic acid, ethyl ester.EXAMPLE 21Ethyl 4 2 chlorophenyl 5 cyano 1,4 dihydro 6 methyl 2 4 pyridinylsulfinyl methyl 3 pyridinecarboxylate mp. 236 237 C.EXAMPLE 2JEthyl 5 cyano 4 2, 3 dichlorophenyl 1, 4 dihydro 6 methyl 2 4 pyridinylsulfinyl methyl 3 pyridinecarboxylate mp.EXAMPLE 2K 5 Cyano 1,4 dihydro 6 methyl 2 2 pyrimidinylsulfinyl methyl 4 trifluoromethyl phenyl 3 pyridinecarboxylic acid, ethyl ester mp 15l l540C dec .EXAMPLE 2L 5 Cyano 1,4 dihydro 6 methyl 2 1 methyl 1H imidazol 2 yl sulfinyl methyll 4 2 trifluoromethyl phenyll 3 pyridinecarboxylic acid, ethyl ester. EXAMPLE 2MEthyl 5 cyano 1,4 dihydro 6 methyl 2 l phenylsulfinyl methyl 4 phenyl 3 pyridinecarboxylate. EXAMPLE 2N 3,5 Pyridinecarboxylic acid, 2 2 chlorophenyl sulfinyl methylene 6 methyl 1,2,3,4 tetrahydro4 2 trifluoromethyl phenyl 3 ethyl 5 methyl ester mp 153 154 0C. EXAMPLE 20 3 Pyridinecarboxylic acid, 5 cyano 4 cyclohexyl l,4 dihydro 6 methyl 2 phenylsulfinyl methyl , ethyl ester mp 144 146 OC EXAMPLE 2P 3 Pyridinecarboxylic acid, 5 cyano 4 2 difluoro methoxy phenyl 1,4 dihydro 6 metfi91 2 phenyl sulfinyl methyl , ethyl ester, mp 122 124 C.EXAMPLE 2Q 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , methyl ester mp 207 210 C.EXAMPLE 2R 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylsulfinyl methyl 4 2 trifluoro methyl phenyl , 1 methylethyl ester Isomer A mp 189 1910C. EXAMPLE 2S 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , 2 hydroxyethyl ester mp 172 173 0C. EXAMPLE 2T 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 4 2 phenyl 1H imidazol 4 yl 2 phenyl sulfinyl methyl , ethyl ester, diastereoisomers mp 211 212 0C. EXAMPLE 2U 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 2 pyridinylsulfinyl methyl 4 12 tri fluoromethyl phenyl , ethyl ester mp l55 l740C dec . EXAMPLE 2V 3 Pyridinecarboxylic acid, 5 cyano 2 2 fluoro phenyl sulfinyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester, diastereoisomers mp 186 187 C.EXAMPLE 2W 3 Pyridinecarboxylic acid, 2 4 acetylamino phenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl a 2 trifluoromethyl phenyl , ethyl ester, mixture of isomers mp 228 2300C. EXAMPLE 2X 3 Pyridinecarboxylic acid, 2 4 chlorophenyl sulfinyl methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 207 210 0C. EXAMPLE 2Y 3 Pyridinecarboxylic acid, 5 cyano 2 1 3,4 dichlorophenyl sulfinyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester, diastereoisomers mp 173 176 C. EXAMPLE 2Z 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl mp 209 211 C.EXAMPLE 2AA 3 Quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydromethyl 5 oxo 2 l phenylsulfinyl methyll 4 2 trifluoromethyl phenyl , ethyl ester mp 177 178 C.EXAMPLE 2BB 3 Quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro5 oxo 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , ethyl ester, t mp 223 2240C. EXAMPLE 2CCEthyl 3 cyano 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl 5 pyridinecarboxylate.EXAMPLE 2DD 3 Pyridinecarboxylic acid, 5 cyano l 2 diethyl amino ethyl 1,4 dihydro 6 methyl 2 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , ethyl ester mixture of isomers mp 128 1310C. EXAMPLE 2EE 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 2 83 methoxy 3 oxopropyl sulfonyl methyl 6 methyl4 2 trifluoromethyl phenyl , ethyl ester mp 135 137 C.EXAMPLE 2FF 3 Pyridinecarboxylic acid, 5 cyano 2 2 ethoxy 2 oxoethyl sulfinyl methyl 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 127 130 0C. EXAMPLE 2GG 2,4 bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro 6 methyl 2 phenylsulfinyl methyl , ethyl ester mp 167 170 0C. By following the procedure described in theExample 2 and using substrates from Example 1Z, the following additional sulfinyl derivatives are obtained. EXAMPLE 2HH 3, 5 Pyridinedicarboxylic acid, 1,4 dihydro 6 methyl 2 t 2 methylphenyl sulfinyl methyl 4 12 trifluoro methyl phenyl , diethyl ester mp 143 1470C Isomer A , mp 140 1440C Isomer B .EXAMPLE 211 3,5 Pyridinedicarboxylic acid, 1,4 dihydro 2 methyl 6 phenylsulfinyl methyl 4 2 trifluoromethyl phenyl , diethyl ester mp 142 143 C.EXAMPLE 2JJ 3,5 Pyridinedicarboxylic acid, 1,4 dihydro 2 methyl6 2 pyridinylsulfinyl methyl 4 2 trifluoromethyl phenyl , diethyl ester mp 182 183 C.EXAMPLE 2KK 3,5 Pyridinedicarboxylic acid, 1,4 dihydro 2 4 methoxyphenyl sulfinyl methyl 6 methyl 4 12 tri fluoromethyl phenyl , diethyl ester Isomer A, mp 190 1910C Isomer B, mp 159 160 C. EXAMPLE 3 3 ,5 Pvridinedicarboxvlic acid, l,4 dibvdro 2 methvl 6 phenylsulfonyl methyl 4 2 trimethyl phenyl diethyl ester m Chloropenbenzoic acid 0.4 g, 0.002 mole is added with stirring to a solution of 0.5 g 0.001 mole of 3,5 pyridinedicarboxylic acid, 1,4 dihydro6 methyl 2 2 phenylthio methyl 4 2 trifluoro methyl phenylidiethyl ester in 20 ml of dichloromethane at room temperature. The reaction mixture is stirred for four hours at room temperature to complete the reaction. The solution is washed successively with dilute sodium bicarbonate solution followed by water, dried, and stripped to give a solid.This is purified by chromatography to give pure 3,5 pyridinedicarboxylic acid, 1,4 dihydro 2 methyl 6 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl diethyl ester mp 194 1950c. Anal. calcd. for C26H26NF3O6S C, 58.04 H, 4.83 N, 2.60 Found C, 58.36 H, 5.14 N, 2.58 Following the procedure of Example 3 and using substrates selected from among Examples 1, additional sulfonyl derivatives were obtained.EXAMPLE 3AEthyl 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl 3 pyridinecarboxylate mp 209 211 C.EXAMPLE 3BEthyl 5 cyano 1,4 dihydro 6 methyl 2 4 methoxyphenyl sulfonyl methyl 4 2 trifluorophenyl 3pyridinecarboxylate mp 205 208 0C EXAMPLE 3CEthyl 5 cyano 1,4 dihydro 6 methyl 2 2 meth phenyl sulfonyl methyl 4 2 trifluorophenyl 3pyridinecarboxylate mp 223 225 C dec .EXAMPLE 3DEthyl 2 2 chlorophenyl sulfonyl methyl 5 cyano 1,4 dihydro 6 methyl 4 t 2 trifluoromethyl phenyl 3 pyridinecarboxylate EXAMPLE 3E 3,5 Pyridinecarboxylic acid, 2 2 chlorophenyl sulfonyl methyl 1,4 dihydro 6 methyl 4 2 tri fluoromethyl phenylj 3 ethyl, 5 methyl ester mp 155 1570C.EXAMPLE 3FEthyl 5 cyano 1,4 dihydro 6 methyl 2 4 pyridinylsulfonyl methyl 4 2 trifluorophenyl phenyl 3pyridinecarboxylate mp 219 220 C dec .EXAMPLE 3G 5 Cyano 1,4 dihydro 6 methyl 2 2 pyridinylsulfonyl methyl 4 2 trifluorophenyl phenyl 3 pyridinecarboxylic acid, ethyl ester, N oxide mp 233 2350C.EXAMPLE 3HEthyl 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 phenyl 3 pyridinecarboxylate.EXAMPLE 3I 2,4 Bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro 6 methyl 2 phenylsulfonyl methyl , ethyl ester, l oxide EXAMPLE 3J 3,4 Bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro 6 methyl 2 phenylsulfonylEmethyl , ethyl ester, mixture of isomers mp 201 202 C.EXAMPLE 3KEthyl 3 cyano 1,4 dihydro 6 methyl 2 phenylsufonyl methyl 4 12 trifluoromethyl phenyl 5 carboxylate. EXAMPLE 3L 3 Pyridinecarboxylic acid, 2 tl 4 aminophenyl sulfonyll methyl 5 cyano 1,4 dihydro 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 237 240 C.EXAMPLE 3M 2,4 Bipyridine 3 carboxylic acid, 5 cyano 1 ,4 dihydro 6 methyl 2 phenylsulfonyl methyl , ethyl ester mp 196 198 C.EXAMPLE 3N 3 Pyridinecarboxylic acid, 5 cyano 4 cyclohexyl6 methyl 1,4 dihydro 2 phenylsulfonyl methyl , ethyl ester mp 150 152 C.EXAMPLE 30 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6methyl 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl , 1 methylethyl ester mp 205 207 C.EXAMPLE 3P 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 12 trifluoro methyl phenyl , 2 propenyl ester mp 187 1890C. EXAMPLE 3Q 3 Pyridinecarboxylic acid, 5 cyano 2 4 1,1 dimethylethyl 2 methylphenyl sulfonyl methyl 1,4 dihydro6 methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 155 159 C.EXAMPLE 3R 3 Pyridinecarboxylic acid, 5 cyano 2 2 fluorophenyl sulfonyl methyl 1,4 dihydro 6 methyl 4 12 trifluoro methyl phenyl , ethyl ester mp 212 213 C. EXAMPLE 3S 3 Pyridinecarboxylic acid, 2 4 chlorophenyl sulfonyl methyll 5 cyano 1,4 dihydro 6 methyl 4 12 trifluoro methyl phenyl , ethyl ester mp 230 233 C. EXAMPLE 3T 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 6 methyl 4 3 nitrophenyl 2 r phenylsulfonyl methyll t ethyl ester mp 175 176 C.EXAMPLE 3U 3 Pyridinecarboxylic acid, 5 cyano l,4 dihydro 6 methyl 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl , 2,3 dihydroxypropyl ester mp 102 103 0C EXAMPLE 3V 3 Pyridinecarboxylic acid, 5 cyano 1,4 dihydro 2 tft3 methoxy 3 oxopropyl sulfonyl methyll 6 methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 119 120 0C EXAMPLE 3W 3 Quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro l methyl 5 oxo 2 phenylsulfonylAmethyl 4 2 tri fluoromethyl phenyl , ethyl ester mp 214 215 C. EXAMPLE 3X 3 Quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro5 oxo 2 phenylsulfonyl methyl 4 2 trifluoromethyl phenyl , ethyl ester mp 235 2360C. EXAMPLE 4 3 Quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro1 methyl 5 oxo 2 8phenylthio methyl 4 2 trifluoromethyl phenyl , ethyl ester To a stirred solution of sodium hydride 40 mg, 60 oil dispersion in 5 ml of tetrahydrofuran is added dropwise a solution of 480 mg of 3 quinolinecarboxylic acid, 1,4,5,6,7,8 hexahydro 5 oxo 2 phenylthio methyl 4 2 trifluoromethyl phenyl ethyl ester, in 15 ml of tetrahydrofuran. Hydrogen is evolved and a bright orange color develops. Methyl iodide 0.9 g is added and the reaction mixture is stirred at room temperature for 2 hours. ShNe solvent is distilled, the residue is treated with water and the organic material is extracted with methylene chloride. The organic extract is separated, dried over anhydrous magnesium sulfate and evaporated to dryness.The residue is crystallized from ether to give 250 mg of the title compound mp 129 130 0C. Anal. calcd. for C27H26F3NO3S C, 64.67 H, 5.19 N, 2.79Found C, 64.75 H, 5.38 N, 2.74 Starting materials for use in preparation of compounds of the present invention are known or may be prepared according to methods analogous to those described below. PREPARATIVE EXAMPLESEthyl 3 oxo 4 4 pyridylthio butanoate see compound of the Formula V in Scheme II, wherein R3 is COVET and R1 is 4 psridvl Ethyl 4 chloroacetoacetate 12.4 g, 0.075 mole is added dropwise with stirring to a suspension of 4 mercaptopyridine 8.3 g, 0.075 mole in a mixture of tetrahydrofuran 80 ml and N,N dimethylformamide 40 ml . Extherm is observed and precipitate begins to appear. The reaction mixture is stirred at ambient temperature for three hours and filtered. The filtrate is stripped to remove solvent and used as is without further purification.Ethyl 3 oxo 4 phenylthio butanoate see compound of the Formula V in Scheme II, wherein R3 is CO2Et and R1 is phenyl Ethyl 4 chloroacetoacetate 15 g, 0.09 mole is added dropwise with stirring to a solution of benzenethiol 10 g, 0.09 mole in pyridine 15 ml , The reaction mixture is stirred for an additional two hours at ambient temperature. The reaction mixture is poured into water and the oil is extracted with ether. The ether extract is washed successively with 1 N HC1, water, dried over anhydrous MgSO4 and evaporated. This material is used as is for the next step without further purification. Anal. calcd. for C12Hl403S C, 60.48 H, 5.92 S, 13.45Found C, 60.18 H, 5.59 S, 14.02 Similarly, by substituting 4 bromo 3 oxo butanenitrile Chem. Ber 115 1 , 355 80 in place of ethyl 4 chloroacetoacetate one obtains 3 oxo 4 phenylthio butanenitrile. Formula V in Scheme II, wherein R3 is CN and R1 is phenyl. FORMULAEMI33.1 SCHEME IEMI34.1 where in n is 1 or 2 where in n is 1 or 2 SCHEME IIEMI35.1 SCHEME IIIEMI36.1